

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020

<https://marketpublishers.com/r/FBF2F4A3AF2EN.html>

Date: March 2020

Pages: 52

Price: US\$ 2,000.00 (Single User License)

ID: FBF2F4A3AF2EN

Abstracts

Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020, provides an overview of the Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline landscape.

Hypoactive sexual desire disorder (HSDD) is an absence of sexual fantasies and desire for sexual activity. The predisposing factors include anxiety, depression, androgen deficiencies, and chronic debilitating illnesses, such as chronic renal failure, hyperprolactinaemia and hypo-hyperthyroid states. Treatment includes antidepressant and hormone therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Hypoactive Sexual Desire Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 6, 1 and 1 respectively.

Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Female Hypoactive Sexual Desire Disorder (Women's Health).

The pipeline guide reviews pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics and enlists all their major

and minor projects.

The pipeline guide evaluates Female Hypoactive Sexual Desire Disorder (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Female Hypoactive Sexual Desire Disorder (Women's Health)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Female Hypoactive Sexual Desire Disorder (Women's Health).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Female Hypoactive Sexual Desire Disorder (Women's Health) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Female Hypoactive Sexual Desire Disorder - Overview
- Female Hypoactive Sexual Desire Disorder - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Female Hypoactive Sexual Desire Disorder - Therapeutics Assessment
 - Assessment by Target
 - Assessment by Mechanism of Action
 - Assessment by Route of Administration
 - Assessment by Molecule Type
- Female Hypoactive Sexual Desire Disorder - Companies Involved in Therapeutics Development
 - Better Life Pharmaceuticals Inc
 - Dare Bioscience Inc
 - Emotional Brain BV
 - EndoCeutics Inc
 - Fabre-Kramer Pharmaceuticals Inc
 - Ivix Ltd
 - Kuhnle Pharmaceutical Co Ltd
 - S1 Biopharma Inc
- Female Hypoactive Sexual Desire Disorder - Drug Profiles
 - (buspirone hydrochloride + testosterone) - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - (sildenafil citrate + testosterone) - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - BP-101 - Drug Profile
 - Product Description
 - Mechanism Of Action
 - R&D Progress
 - gepirone hydrochloride ER - Drug Profile
 - Product Description

Mechanism Of Action

R&D Progress

KI-1120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGSN-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sildenafil citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SIP-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Female Hypoactive Sexual Desire Disorder - Dormant Projects

Female Hypoactive Sexual Desire Disorder - Discontinued Products

Female Hypoactive Sexual Desire Disorder - Product Development Milestones

Featured News & Press Releases

Mar 09, 2020: Dare Bioscience presents positive Sildenafil Cream, 3.6% data supporting further development for the treatment of female sexual arousal disorder

Dec 11, 2019: Dar? Bioscience announces alignment with the FDA on phase 2b study design and novel primary endpoint PRO instruments to support the continued clinical development of Sildenafil Cream, 3.6%, a potential therapy for Female Sexual Arousal Disorder

Oct 28, 2019: Dare Bioscience and Strategic Science & Technologies announce presentation of positive findings from thermography clinical study of Sildenafil Cream, 3.6 % in healthy women at the Sexual Medicine Society of North America Conference

Sep 12, 2019: Ovoca announces filing of marketing authorisation application with Russian Ministry of Health for BP-101

Jun 17, 2019: Dar? Bioscience announces positive results in Thermography feasibility study with Sildenafil Cream, 3.6%, a potential therapy for female sexual arousal

disorder

Apr 23, 2019: Ovoca Bio announced US and EU clinical development plans

Mar 25, 2019: Ovoca Bio Libicore (BP-101) meets primary/secondary endpoints in phase 3 trial for hypoactive sexual desire disorder ahead of time

Mar 18, 2019: Dare Bioscience to present update on Sildenafil Cream at 31st Annual ROTH Conference

Jan 04, 2019: S1 Biopharma announces expanded analysis of phase 2a data on Lorexys for treatment of hypoactive sexual desire disorder based on PGIC scale to be presented at 2019 ISSWSH/ISSM joint meeting

Dec 20, 2018: S1 Biopharma granted patents for Lorexys in Europe and Asia for treatment of hypoactive sexual desire disorder

Jan 09, 2018: Emotional Brain FSIAD Product Lybridos shows High Efficacy and Safety in Phase 2B Trials

Jan 09, 2018: Emotional Brain's FSIAD Product Lybrido shows High Efficacy and Safety in Phase 2B Trials

Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference

Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder

May 01, 2015: Emotional Brain Prepares for the Last Stage in Clinical Development of Medicines for Sexual Dysfunction in Women

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Female Hypoactive Sexual Desire Disorder - Pipeline by Better Life Pharmaceuticals Inc, H1 2020

Female Hypoactive Sexual Desire Disorder - Pipeline by Dare Bioscience Inc, H1 2020

Female Hypoactive Sexual Desire Disorder - Pipeline by Emotional Brain BV, H1 2020

Female Hypoactive Sexual Desire Disorder - Pipeline by EndoCeutics Inc, H1 2020

Female Hypoactive Sexual Desire Disorder - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2020

Female Hypoactive Sexual Desire Disorder - Pipeline by Ivix Ltd, H1 2020

Female Hypoactive Sexual Desire Disorder - Pipeline by Kuhnle Pharmaceutical Co Ltd, H1 2020

Female Hypoactive Sexual Desire Disorder - Pipeline by S1 Biopharma Inc, H1 2020

Female Hypoactive Sexual Desire Disorder - Dormant Projects, H1 2020

Female Hypoactive Sexual Desire Disorder - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Female Hypoactive Sexual Desire Disorder, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Better Life Pharmaceuticals Inc

Dare Bioscience Inc

Emotional Brain BV

EndoCeutics Inc

Fabre-Kramer Pharmaceuticals Inc

Ivix Ltd

Kuhnle Pharmaceutical Co Ltd

S1 Biopharma Inc

I would like to order

Product name: Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/FBF2F4A3AF2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/FBF2F4A3AF2EN.html>